| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hematopoietic Stem Cell Transplantation | 32 | 2024 | 1193 | 2.730 |
Why?
|
| Graft vs Host Disease | 15 | 2024 | 543 | 1.460 |
Why?
|
| Hodgkin Disease | 8 | 2022 | 294 | 1.220 |
Why?
|
| T-Lymphocytes | 16 | 2024 | 1679 | 1.170 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 7 | 2016 | 184 | 0.920 |
Why?
|
| Salvage Therapy | 3 | 2021 | 193 | 0.890 |
Why?
|
| Lymphoma | 4 | 2021 | 324 | 0.800 |
Why?
|
| Antigens, Neoplasm | 5 | 2021 | 392 | 0.760 |
Why?
|
| Transplantation, Autologous | 13 | 2022 | 300 | 0.710 |
Why?
|
| Cell- and Tissue-Based Therapy | 2 | 2021 | 155 | 0.700 |
Why?
|
| Transplantation, Homologous | 20 | 2024 | 660 | 0.650 |
Why?
|
| Herpesvirus 4, Human | 11 | 2018 | 663 | 0.580 |
Why?
|
| Immunosuppressive Agents | 4 | 2014 | 646 | 0.570 |
Why?
|
| Bone Marrow Transplantation | 5 | 2014 | 581 | 0.570 |
Why?
|
| Transplantation Conditioning | 9 | 2022 | 323 | 0.550 |
Why?
|
| T-Lymphocytes, Cytotoxic | 8 | 2013 | 504 | 0.530 |
Why?
|
| Immunotherapy, Adoptive | 7 | 2018 | 789 | 0.490 |
Why?
|
| Alemtuzumab | 7 | 2024 | 88 | 0.460 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 5 | 2013 | 803 | 0.460 |
Why?
|
| Skin Ulcer | 1 | 2014 | 32 | 0.460 |
Why?
|
| Thalidomide | 1 | 2014 | 36 | 0.460 |
Why?
|
| Middle Aged | 42 | 2024 | 25798 | 0.430 |
Why?
|
| Multiple Myeloma | 3 | 2021 | 170 | 0.420 |
Why?
|
| Lymphoma, T-Cell | 2 | 2018 | 65 | 0.410 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 5 | 2013 | 98 | 0.390 |
Why?
|
| Herpesvirus 6, Human | 3 | 2017 | 59 | 0.380 |
Why?
|
| Adult | 40 | 2024 | 28926 | 0.380 |
Why?
|
| Antibodies, Monoclonal | 6 | 2008 | 1021 | 0.370 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 3 | 2016 | 137 | 0.360 |
Why?
|
| Roseolovirus Infections | 2 | 2007 | 33 | 0.350 |
Why?
|
| Stem Cell Transplantation | 4 | 2006 | 239 | 0.350 |
Why?
|
| Antigens, CD19 | 6 | 2018 | 177 | 0.340 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2022 | 1119 | 0.330 |
Why?
|
| Antilymphocyte Serum | 3 | 2006 | 56 | 0.330 |
Why?
|
| Aged | 25 | 2024 | 18917 | 0.320 |
Why?
|
| Interleukin-2 | 4 | 2014 | 236 | 0.320 |
Why?
|
| Gout | 1 | 2011 | 142 | 0.310 |
Why?
|
| Male | 51 | 2024 | 59866 | 0.310 |
Why?
|
| Burkitt Lymphoma | 2 | 2006 | 146 | 0.300 |
Why?
|
| CD40 Ligand | 4 | 2011 | 64 | 0.300 |
Why?
|
| Leukemia | 3 | 2022 | 376 | 0.300 |
Why?
|
| Lymphoma, Follicular | 1 | 2007 | 29 | 0.290 |
Why?
|
| Paramyxoviridae Infections | 1 | 2007 | 44 | 0.280 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 3 | 2013 | 29 | 0.280 |
Why?
|
| Metapneumovirus | 1 | 2007 | 51 | 0.280 |
Why?
|
| Humans | 68 | 2024 | 122853 | 0.280 |
Why?
|
| Lymphoma, Non-Hodgkin | 3 | 2018 | 162 | 0.280 |
Why?
|
| Paresis | 1 | 2006 | 36 | 0.280 |
Why?
|
| Rituximab | 3 | 2022 | 158 | 0.270 |
Why?
|
| Hemoglobin SC Disease | 1 | 2006 | 12 | 0.270 |
Why?
|
| Cancer Vaccines | 4 | 2011 | 187 | 0.270 |
Why?
|
| Viral Matrix Proteins | 5 | 2018 | 109 | 0.270 |
Why?
|
| Cytomegalovirus Infections | 2 | 2024 | 219 | 0.260 |
Why?
|
| Receptors, Antigen, T-Cell | 3 | 2020 | 479 | 0.260 |
Why?
|
| Leukemia, Myeloid | 1 | 2006 | 85 | 0.260 |
Why?
|
| Cytokines | 1 | 2011 | 1287 | 0.260 |
Why?
|
| Female | 46 | 2024 | 65278 | 0.250 |
Why?
|
| Hematologic Neoplasms | 5 | 2021 | 272 | 0.250 |
Why?
|
| Young Adult | 11 | 2022 | 8826 | 0.250 |
Why?
|
| Antibodies, Neoplasm | 5 | 2008 | 58 | 0.250 |
Why?
|
| Antiviral Agents | 2 | 2024 | 736 | 0.240 |
Why?
|
| Lymphoma, B-Cell | 3 | 2018 | 137 | 0.240 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2022 | 1250 | 0.220 |
Why?
|
| Genetic Therapy | 3 | 2018 | 706 | 0.220 |
Why?
|
| Quinazolines | 1 | 2024 | 175 | 0.220 |
Why?
|
| Tissue Donors | 6 | 2021 | 497 | 0.220 |
Why?
|
| Autoimmune Diseases | 2 | 2018 | 250 | 0.210 |
Why?
|
| Adolescent | 17 | 2022 | 19037 | 0.210 |
Why?
|
| Recurrence | 10 | 2022 | 1419 | 0.210 |
Why?
|
| Treatment Outcome | 19 | 2018 | 12070 | 0.210 |
Why?
|
| Lymphocyte Transfusion | 2 | 2021 | 58 | 0.200 |
Why?
|
| Carmustine | 1 | 2022 | 26 | 0.200 |
Why?
|
| Neomycin | 2 | 2000 | 37 | 0.200 |
Why?
|
| Graft vs Leukemia Effect | 2 | 2021 | 30 | 0.200 |
Why?
|
| Melphalan | 1 | 2022 | 49 | 0.200 |
Why?
|
| Bone Marrow | 2 | 2021 | 319 | 0.200 |
Why?
|
| Cytarabine | 1 | 2022 | 99 | 0.200 |
Why?
|
| Seizures | 1 | 2006 | 875 | 0.190 |
Why?
|
| Leukemia, Myeloid, Acute | 3 | 2021 | 532 | 0.180 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2021 | 137 | 0.170 |
Why?
|
| Bone Marrow Cells | 1 | 2021 | 261 | 0.170 |
Why?
|
| Tumor Escape | 2 | 2018 | 62 | 0.160 |
Why?
|
| Photosensitivity Disorders | 1 | 2018 | 10 | 0.160 |
Why?
|
| Lymphocyte Depletion | 3 | 2024 | 123 | 0.160 |
Why?
|
| Voriconazole | 1 | 2018 | 35 | 0.160 |
Why?
|
| Acute Disease | 4 | 2011 | 1092 | 0.150 |
Why?
|
| Antigens, CD | 4 | 2011 | 422 | 0.150 |
Why?
|
| Granulomatous Disease, Chronic | 1 | 2018 | 65 | 0.150 |
Why?
|
| Antipyrine | 2 | 1988 | 4 | 0.150 |
Why?
|
| DNA Virus Infections | 1 | 2017 | 22 | 0.150 |
Why?
|
| Diltiazem | 2 | 1988 | 13 | 0.150 |
Why?
|
| DNA Viruses | 1 | 2017 | 33 | 0.140 |
Why?
|
| Epstein-Barr Virus Infections | 2 | 2018 | 285 | 0.140 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 2 | 2006 | 38 | 0.140 |
Why?
|
| Child | 16 | 2022 | 24168 | 0.140 |
Why?
|
| Immunoglobulin kappa-Chains | 1 | 2016 | 31 | 0.130 |
Why?
|
| Retrospective Studies | 10 | 2024 | 15927 | 0.130 |
Why?
|
| Genetic Markers | 1 | 1998 | 597 | 0.130 |
Why?
|
| Prognosis | 4 | 2021 | 4498 | 0.130 |
Why?
|
| Diagnostic Imaging | 1 | 2016 | 273 | 0.120 |
Why?
|
| Vidarabine | 3 | 2010 | 79 | 0.120 |
Why?
|
| Leukapheresis | 1 | 2013 | 13 | 0.110 |
Why?
|
| Blood Donors | 1 | 2013 | 62 | 0.110 |
Why?
|
| Lung Diseases | 2 | 2009 | 385 | 0.110 |
Why?
|
| Viruses | 1 | 2014 | 123 | 0.110 |
Why?
|
| Time Factors | 7 | 2018 | 6202 | 0.110 |
Why?
|
| Remission Induction | 5 | 2016 | 301 | 0.100 |
Why?
|
| Combined Modality Therapy | 4 | 2021 | 1246 | 0.100 |
Why?
|
| Azoles | 1 | 2012 | 9 | 0.100 |
Why?
|
| Cushing Syndrome | 1 | 2012 | 17 | 0.100 |
Why?
|
| Budesonide | 1 | 2012 | 19 | 0.100 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2014 | 216 | 0.100 |
Why?
|
| Quality of Life | 1 | 2021 | 1918 | 0.100 |
Why?
|
| Gene Transfer Techniques | 2 | 2011 | 374 | 0.100 |
Why?
|
| Colchicine | 1 | 2011 | 43 | 0.100 |
Why?
|
| Immunophenotyping | 4 | 2016 | 332 | 0.100 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 2 | 2013 | 63 | 0.100 |
Why?
|
| Virus Diseases | 1 | 2014 | 280 | 0.090 |
Why?
|
| Cytomegalovirus | 3 | 2024 | 269 | 0.090 |
Why?
|
| Retroviridae | 3 | 2016 | 205 | 0.090 |
Why?
|
| CD28 Antigens | 1 | 2011 | 78 | 0.090 |
Why?
|
| Hematopoietic Stem Cells | 2 | 2013 | 541 | 0.090 |
Why?
|
| Allopurinol | 1 | 2011 | 70 | 0.090 |
Why?
|
| B-Lymphocytes | 1 | 2013 | 520 | 0.090 |
Why?
|
| Primary Myelofibrosis | 1 | 2011 | 50 | 0.090 |
Why?
|
| Steroids | 1 | 2011 | 203 | 0.090 |
Why?
|
| Follow-Up Studies | 5 | 2018 | 5017 | 0.090 |
Why?
|
| Transplantation Chimera | 2 | 2008 | 39 | 0.090 |
Why?
|
| Lymphocyte Subsets | 1 | 2009 | 38 | 0.080 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2012 | 279 | 0.080 |
Why?
|
| Cell Proliferation | 5 | 2018 | 2321 | 0.080 |
Why?
|
| Neoplasm Staging | 2 | 2016 | 1222 | 0.080 |
Why?
|
| DNA, Viral | 2 | 2007 | 492 | 0.080 |
Why?
|
| Histocompatibility | 2 | 2006 | 46 | 0.080 |
Why?
|
| Adenoviridae | 4 | 2013 | 636 | 0.080 |
Why?
|
| Theophylline | 1 | 1988 | 29 | 0.080 |
Why?
|
| Verapamil | 1 | 1988 | 52 | 0.080 |
Why?
|
| Virus Integration | 1 | 2007 | 44 | 0.070 |
Why?
|
| Lymphocyte Activation | 3 | 2018 | 679 | 0.070 |
Why?
|
| Body Mass Index | 1 | 2013 | 1468 | 0.070 |
Why?
|
| Antigens, CD34 | 1 | 2007 | 108 | 0.070 |
Why?
|
| Encephalitis, Viral | 1 | 2007 | 22 | 0.070 |
Why?
|
| Positron Emission Tomography Computed Tomography | 2 | 2018 | 77 | 0.070 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 2008 | 145 | 0.070 |
Why?
|
| Antigen-Presenting Cells | 1 | 2007 | 118 | 0.070 |
Why?
|
| Minoxidil | 1 | 1986 | 5 | 0.070 |
Why?
|
| Exchange Transfusion, Whole Blood | 1 | 2006 | 14 | 0.070 |
Why?
|
| Survival Analysis | 4 | 2016 | 1473 | 0.070 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2006 | 474 | 0.070 |
Why?
|
| Filgrastim | 1 | 2006 | 15 | 0.070 |
Why?
|
| Anemia, Aplastic | 1 | 2006 | 53 | 0.070 |
Why?
|
| Anti-Bacterial Agents | 1 | 1998 | 2396 | 0.070 |
Why?
|
| Feasibility Studies | 3 | 2016 | 754 | 0.070 |
Why?
|
| Immune System Diseases | 1 | 2006 | 45 | 0.070 |
Why?
|
| Benzazepines | 1 | 1986 | 64 | 0.070 |
Why?
|
| Major Histocompatibility Complex | 1 | 2006 | 51 | 0.070 |
Why?
|
| Antibodies, Monoclonal, Humanized | 5 | 2008 | 501 | 0.060 |
Why?
|
| Leukemia, B-Cell | 1 | 2005 | 26 | 0.060 |
Why?
|
| Antineoplastic Agents | 3 | 2013 | 1682 | 0.060 |
Why?
|
| Lymphocyte Count | 3 | 2014 | 114 | 0.060 |
Why?
|
| Disease-Free Survival | 3 | 2013 | 868 | 0.060 |
Why?
|
| Leukocyte Common Antigens | 1 | 2005 | 91 | 0.060 |
Why?
|
| Cell Culture Techniques | 1 | 2006 | 288 | 0.060 |
Why?
|
| Graft Rejection | 1 | 2008 | 584 | 0.060 |
Why?
|
| Acetates | 1 | 2024 | 72 | 0.060 |
Why?
|
| Gene Rearrangement, beta-Chain T-Cell Antigen Receptor | 1 | 2004 | 12 | 0.060 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2010 | 714 | 0.060 |
Why?
|
| Myelin Basic Protein | 1 | 2004 | 69 | 0.060 |
Why?
|
| Drug Interactions | 3 | 2012 | 252 | 0.060 |
Why?
|
| Phosphoproteins | 1 | 2006 | 402 | 0.060 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2006 | 401 | 0.060 |
Why?
|
| Herpesviridae Infections | 1 | 2004 | 144 | 0.060 |
Why?
|
| Recovery of Function | 1 | 2005 | 433 | 0.050 |
Why?
|
| Autoantigens | 1 | 2004 | 133 | 0.050 |
Why?
|
| Child, Preschool | 7 | 2018 | 13858 | 0.050 |
Why?
|
| Cell Line | 3 | 2013 | 2787 | 0.050 |
Why?
|
| Glycoproteins | 1 | 2005 | 372 | 0.050 |
Why?
|
| Recombinant Proteins | 1 | 2006 | 1404 | 0.050 |
Why?
|
| Genetic Vectors | 2 | 2013 | 973 | 0.050 |
Why?
|
| Positron-Emission Tomography | 2 | 2016 | 289 | 0.050 |
Why?
|
| Lymphoma, AIDS-Related | 1 | 2002 | 37 | 0.050 |
Why?
|
| Lymphocytes | 1 | 2023 | 404 | 0.050 |
Why?
|
| Graft Survival | 3 | 2011 | 526 | 0.050 |
Why?
|
| T-Cell Antigen Receptor Specificity | 1 | 2021 | 58 | 0.050 |
Why?
|
| Antibodies, Viral | 1 | 2007 | 1138 | 0.050 |
Why?
|
| Multiple Sclerosis | 1 | 2004 | 334 | 0.040 |
Why?
|
| Allografts | 1 | 2021 | 190 | 0.040 |
Why?
|
| Demography | 1 | 2021 | 238 | 0.040 |
Why?
|
| CD5 Antigens | 2 | 2010 | 37 | 0.040 |
Why?
|
| Nuclear Proteins | 1 | 2006 | 1283 | 0.040 |
Why?
|
| Liver | 1 | 1986 | 1858 | 0.040 |
Why?
|
| Anti-HIV Agents | 1 | 2002 | 304 | 0.040 |
Why?
|
| Philadelphia Chromosome | 1 | 1998 | 39 | 0.040 |
Why?
|
| Chimerism | 1 | 2018 | 28 | 0.040 |
Why?
|
| Guillain-Barre Syndrome | 1 | 2018 | 28 | 0.040 |
Why?
|
| Pancytopenia | 1 | 2018 | 40 | 0.040 |
Why?
|
| Genes, Viral | 1 | 1998 | 186 | 0.040 |
Why?
|
| Injections, Intravenous | 1 | 1998 | 254 | 0.040 |
Why?
|
| Unrelated Donors | 1 | 2018 | 82 | 0.040 |
Why?
|
| Drug Resistance, Microbial | 1 | 1998 | 193 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2013 | 1006 | 0.040 |
Why?
|
| Red-Cell Aplasia, Pure | 1 | 1997 | 3 | 0.040 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 1998 | 98 | 0.040 |
Why?
|
| Sarcoidosis | 1 | 1998 | 64 | 0.040 |
Why?
|
| Mitosporic Fungi | 1 | 1997 | 9 | 0.040 |
Why?
|
| Erythropoiesis | 1 | 1997 | 40 | 0.040 |
Why?
|
| Administration, Oral | 2 | 2012 | 669 | 0.040 |
Why?
|
| Adenoviruses, Human | 1 | 2017 | 82 | 0.040 |
Why?
|
| Cells, Cultured | 2 | 2018 | 3075 | 0.040 |
Why?
|
| BK Virus | 1 | 2017 | 60 | 0.030 |
Why?
|
| Skin Diseases | 1 | 1998 | 122 | 0.030 |
Why?
|
| Interferon-alpha | 1 | 1998 | 221 | 0.030 |
Why?
|
| Whole-Body Irradiation | 2 | 2006 | 66 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2016 | 2047 | 0.030 |
Why?
|
| Workflow | 1 | 2016 | 114 | 0.030 |
Why?
|
| Mycoses | 1 | 1997 | 117 | 0.030 |
Why?
|
| Antifungal Agents | 1 | 2018 | 293 | 0.030 |
Why?
|
| Prospective Studies | 3 | 2014 | 5996 | 0.030 |
Why?
|
| Adoptive Transfer | 1 | 2016 | 237 | 0.030 |
Why?
|
| Phenotype | 2 | 2018 | 4220 | 0.030 |
Why?
|
| Postoperative Care | 1 | 2016 | 292 | 0.030 |
Why?
|
| Kinetics | 2 | 1986 | 1316 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2016 | 816 | 0.030 |
Why?
|
| Tumor Microenvironment | 1 | 2018 | 538 | 0.030 |
Why?
|
| Monitoring, Physiologic | 1 | 2016 | 359 | 0.030 |
Why?
|
| Hepatitis C | 1 | 1997 | 368 | 0.030 |
Why?
|
| Species Specificity | 1 | 2014 | 552 | 0.030 |
Why?
|
| Blood Cell Count | 1 | 2013 | 69 | 0.030 |
Why?
|
| Protein Engineering | 1 | 2013 | 73 | 0.030 |
Why?
|
| Etoposide | 1 | 2013 | 119 | 0.030 |
Why?
|
| Transduction, Genetic | 1 | 2013 | 298 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2007 | 1302 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2021 | 3319 | 0.030 |
Why?
|
| Immunotherapy | 2 | 2011 | 656 | 0.030 |
Why?
|
| South America | 1 | 2012 | 38 | 0.030 |
Why?
|
| Cell Separation | 1 | 2013 | 240 | 0.030 |
Why?
|
| North America | 1 | 2012 | 234 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2014 | 811 | 0.020 |
Why?
|
| Iatrogenic Disease | 1 | 2012 | 132 | 0.020 |
Why?
|
| Cyclophosphamide | 1 | 2013 | 422 | 0.020 |
Why?
|
| Epidemiologic Methods | 1 | 2011 | 107 | 0.020 |
Why?
|
| Infant | 3 | 2014 | 12355 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 2011 | 322 | 0.020 |
Why?
|
| Incidence | 1 | 2018 | 3033 | 0.020 |
Why?
|
| Risk Factors | 3 | 2013 | 9928 | 0.020 |
Why?
|
| Plasmids | 1 | 2011 | 516 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2014 | 1689 | 0.020 |
Why?
|
| Hyaluronan Receptors | 1 | 2010 | 66 | 0.020 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2010 | 149 | 0.020 |
Why?
|
| Stem Cells | 1 | 2014 | 713 | 0.020 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2009 | 158 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2011 | 751 | 0.020 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2009 | 111 | 0.020 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2010 | 191 | 0.020 |
Why?
|
| Medical Records | 1 | 2009 | 189 | 0.020 |
Why?
|
| Immunity | 1 | 2009 | 183 | 0.020 |
Why?
|
| Gene Expression | 1 | 2013 | 1592 | 0.020 |
Why?
|
| Cytochrome P-450 Enzyme Inhibitors | 1 | 1988 | 4 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2012 | 1290 | 0.020 |
Why?
|
| Immunization | 1 | 2010 | 308 | 0.020 |
Why?
|
| Living Donors | 1 | 2008 | 111 | 0.020 |
Why?
|
| Gastrointestinal Diseases | 1 | 2012 | 336 | 0.020 |
Why?
|
| Severe Combined Immunodeficiency | 1 | 2008 | 106 | 0.020 |
Why?
|
| Metabolic Clearance Rate | 1 | 1988 | 142 | 0.020 |
Why?
|
| Half-Life | 1 | 1988 | 157 | 0.020 |
Why?
|
| Cerebrospinal Fluid Proteins | 1 | 2007 | 22 | 0.020 |
Why?
|
| Radiography | 1 | 2009 | 806 | 0.020 |
Why?
|
| Metabolic Diseases | 1 | 2008 | 130 | 0.020 |
Why?
|
| Chemistry | 1 | 1986 | 59 | 0.020 |
Why?
|
| Electrochemistry | 1 | 1986 | 22 | 0.020 |
Why?
|
| Chemical Phenomena | 1 | 1986 | 84 | 0.020 |
Why?
|
| Drug Stability | 1 | 1986 | 55 | 0.020 |
Why?
|
| Respiratory Tract Infections | 1 | 2009 | 263 | 0.020 |
Why?
|
| Tacrolimus | 1 | 2006 | 99 | 0.020 |
Why?
|
| Cyclosporine | 1 | 2006 | 146 | 0.020 |
Why?
|
| United States | 1 | 2021 | 10538 | 0.020 |
Why?
|
| Receptors, Interleukin-2 | 1 | 2005 | 43 | 0.020 |
Why?
|
| B7-2 Antigen | 1 | 2005 | 16 | 0.020 |
Why?
|
| Pneumonia | 1 | 2009 | 327 | 0.020 |
Why?
|
| Siblings | 1 | 2006 | 193 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 1986 | 339 | 0.020 |
Why?
|
| CD52 Antigen | 1 | 2005 | 7 | 0.020 |
Why?
|
| Biopsy | 1 | 2009 | 1256 | 0.020 |
Why?
|
| CD3 Complex | 1 | 2005 | 84 | 0.020 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2005 | 77 | 0.020 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2006 | 195 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2010 | 677 | 0.020 |
Why?
|
| Virus Activation | 1 | 2005 | 86 | 0.020 |
Why?
|
| Texas | 1 | 2013 | 3542 | 0.020 |
Why?
|
| Immune System | 1 | 2005 | 86 | 0.020 |
Why?
|
| Coculture Techniques | 1 | 2005 | 234 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2005 | 309 | 0.020 |
Why?
|
| Histocompatibility Testing | 1 | 2005 | 148 | 0.020 |
Why?
|
| Methotrexate | 1 | 2006 | 342 | 0.010 |
Why?
|
| Age Factors | 1 | 2011 | 2796 | 0.010 |
Why?
|
| Age Distribution | 1 | 2005 | 403 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2008 | 1378 | 0.010 |
Why?
|
| Genes, Immunoglobulin | 1 | 2004 | 33 | 0.010 |
Why?
|
| Immunoglobulin Variable Region | 1 | 2004 | 50 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2009 | 2094 | 0.010 |
Why?
|
| Thymus Gland | 1 | 2004 | 100 | 0.010 |
Why?
|
| Platelet Transfusion | 1 | 2004 | 53 | 0.010 |
Why?
|
| Antigens, Viral | 1 | 2005 | 441 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2011 | 1936 | 0.010 |
Why?
|
| Survival Rate | 1 | 2008 | 1998 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2007 | 1598 | 0.010 |
Why?
|
| Radiography, Thoracic | 1 | 2004 | 156 | 0.010 |
Why?
|
| Forkhead Transcription Factors | 1 | 2005 | 371 | 0.010 |
Why?
|
| Viral Load | 1 | 2004 | 384 | 0.010 |
Why?
|
| Interleukin-10 | 1 | 2004 | 172 | 0.010 |
Why?
|
| Cell Division | 1 | 2004 | 793 | 0.010 |
Why?
|
| Antibodies | 1 | 2004 | 371 | 0.010 |
Why?
|
| Horses | 1 | 2001 | 89 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 2004 | 512 | 0.010 |
Why?
|
| Cell Movement | 1 | 2004 | 838 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2004 | 672 | 0.010 |
Why?
|
| Drug Resistance | 1 | 2001 | 257 | 0.010 |
Why?
|
| Rabbits | 1 | 2001 | 717 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2011 | 6325 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2001 | 731 | 0.010 |
Why?
|
| Data Collection | 1 | 2001 | 383 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 2009 | 1586 | 0.010 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2001 | 316 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2005 | 3299 | 0.010 |
Why?
|
| Erythroid Precursor Cells | 1 | 1997 | 24 | 0.010 |
Why?
|
| Aspergillus fumigatus | 1 | 1997 | 41 | 0.010 |
Why?
|
| Global Health | 1 | 2001 | 557 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2006 | 3001 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2001 | 1246 | 0.010 |
Why?
|
| HIV Infections | 1 | 2002 | 1862 | 0.010 |
Why?
|
| Animals | 1 | 2001 | 33923 | 0.000 |
Why?
|